Corporate Profile

Cortexyme is a biopharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is enrolling patients in a Phase 2/3 clinical trial of its lead small molecule in mild to moderate Alzheimer's disease.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Relations

News Releases

22 Jul '21
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 22, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases , announced that it